The stock price of MaxCyte Inc (NASDAQ: MXCT) has dropped by -1.86 compared to previous close of 2.15. Despite this, the company has seen a fall of -8.26% in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MXCT is 97.94M and currently, short sellers hold a 3.61% of that float. On June 19, 2025, MXCT’s average trading volume was 880.47K shares.
MXCT’s Market Performance
MXCT stock saw a decrease of -8.26% in the past week, with a monthly decline of -7.46% and a quarterly a decrease of -35.47%. The volatility ratio for the week is 2.58%, and the volatility levels for the last 30 days are 4.28% for MaxCyte Inc (MXCT). The simple moving average for the past 20 days is -6.16% for MXCT’s stock, with a -39.46% simple moving average for the past 200 days.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at -13.37% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Soleymannezhad Ali, who sale 1,211 shares at the price of $3.18 back on Mar 18 ’25. After this action, Soleymannezhad Ali now owns 59,439 shares of MaxCyte Inc, valued at $3,850 using the latest closing price.
Sandoval David I., the GENERAL COUNSEL of MaxCyte Inc, sale 353 shares at $3.18 during a trade that took place back on Mar 18 ’25, which means that Sandoval David I. is holding 64,219 shares at $1,122 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.33 for the present operating margin
- 0.78 for the gross margin
The net margin for MaxCyte Inc stands at -1.11. The total capital return value is set at -0.23. Equity return is now at value -19.63, with -17.13 for asset returns.
Based on MaxCyte Inc (MXCT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -1.67.
Currently, EBITDA for the company is -46.41 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 5.83. The receivables turnover for the company is 6.82for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.23.
Conclusion
To wrap up, the performance of MaxCyte Inc (MXCT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
